NO20090451L - Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) - Google Patents

Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol)

Info

Publication number: NO20090451L
Authority: NO; Norway
Prior art keywords: pro; igf; variant; pegylated; glucole
Prior art date: 2006-08-31

Application number

NO20090451A

Other languages

English (en)

Norwegian (no)

Inventor

Stephan Fischer

Friederike Hesse

Kurt Lang

Friedrich Metzger

Jorg Regula

Andreas Schaubmar

Hendrik Knoetgen

Christian Schantz

Hans Joachim Schoenfeld

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-31

Filing date

2009-01-29

Publication date

2009-02-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37667695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090451(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-02-26 Publication of NO20090451L publication Critical patent/NO20090451L/no

Links

238000000034 method Methods 0.000 title abstract 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 title 1
239000005977 Ethylene Substances 0.000 title 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title 1
102100037852 Insulin-like growth factor I Human genes 0.000 title 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 7
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 7
150000001413 amino acids Chemical class 0.000 abstract 3
102000037865 fusion proteins Human genes 0.000 abstract 3
108020001507 fusion proteins Proteins 0.000 abstract 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
238000011084 recovery Methods 0.000 abstract 2
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 abstract 1
108010002231 IgA-specific serine endopeptidase Proteins 0.000 abstract 1
RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 abstract 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 abstract 1
ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 abstract 1
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 abstract 1
GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 abstract 1
QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 abstract 1
108010087924 alanylproline Proteins 0.000 abstract 1
108010060035 arginylproline Proteins 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
238000012258 culturing Methods 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 abstract 1
108010077515 glycylproline Proteins 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000006320 pegylation Effects 0.000 abstract 1
108010029020 prolylglycine Proteins 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20090451A 2006-08-31 2009-01-29 Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) NO20090451L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06018170		2006-08-31
PCT/EP2007/007540 WO2008025528A1 (fr)	2006-08-31	2007-08-29	Procédés de production de conjugués de facteurs de croissance i de type insuline (igf-i) et de polyéthylène glycol

Publications (1)

Publication Number	Publication Date
NO20090451L true NO20090451L (no)	2009-02-26

Family

ID=37667695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090451A NO20090451L (no)	2006-08-31	2009-01-29	Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol)

Country Status (21)

Country	Link
US (4)	US7625996B2 (fr)
EP (1)	EP2059261B1 (fr)
JP (1)	JP5184532B2 (fr)
KR (1)	KR101106931B1 (fr)
CN (1)	CN101511390B (fr)
AR (1)	AR062575A1 (fr)
AU (1)	AU2007291502B2 (fr)
BR (1)	BRPI0715943A2 (fr)
CA (1)	CA2662062C (fr)
CL (1)	CL2007002502A1 (fr)
CO (1)	CO6251278A2 (fr)
CR (1)	CR10591A (fr)
ES (1)	ES2397660T3 (fr)
IL (1)	IL196736A (fr)
MA (1)	MA30660B1 (fr)
MX (1)	MX2009002011A (fr)
NO (1)	NO20090451L (fr)
PE (1)	PE20080912A1 (fr)
RU (1)	RU2009106118A (fr)
TW (1)	TW200819468A (fr)
WO (1)	WO2008025528A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1674113A1 (fr)	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Conjugués de l'IGF-1 et du poly(éthylène glycol)
CA2822302A1 (fr)	2006-02-13	2007-08-23	Alethia Biotherapeutics Inc.	Procedes pour alterer la differenciation osteoclaste
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CL2007002502A1 (es)	2006-08-31	2008-05-30	Hoffmann La Roche	Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja)	2006-08-31	2012-06-20	エフ．ホフマン−ラロシュアーゲー	インスリン様増殖因子ｉの製造方法
EP2249853A4 (fr)	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	Promédicaments peptidiques à base d' esters
JP5173018B2 (ja) *	2008-04-03	2013-03-27	エフ．ホフマン−ラロシュアーゲー	神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
AU2009335715B2 (en)	2008-12-19	2016-09-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
JP5789515B2 (ja)	2008-12-19	2015-10-07	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン類似体
EP2376099A4 (fr) *	2008-12-19	2012-04-25	Univ Indiana Res & Tech Corp	Facteurs de croissance semblables à l'insuline à base d'yl exprimant une haute activité au récepteur de l'insuline
US20110152188A1 (en) *	2009-12-23	2011-06-23	Hanns-Christian Mahler	Pharmaceutical compositions of igf/i proteins
CA2786340C (fr) *	2010-02-11	2017-08-22	F. Hoffmann-La Roche Ag	Conjugues de l'igf-i et du poly(ethylene glycol)
JP5969469B2 (ja)	2010-06-16	2016-08-17	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585102B1 (fr)	2010-06-24	2015-05-06	Indiana University Research and Technology Corporation	Promédicaments insuliniques à base d'amide
GB201012784D0 (en) *	2010-07-29	2010-09-15	Ucb Pharma Sa	Method
BR112014015156A2 (pt)	2011-12-20	2020-10-27	Indiana University Research And Technology Corporation	análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
HK1210192A1 (en)	2012-07-19	2016-04-15	Alethia Biotherapeutics Inc.	Anti-siglec-15 antibodies
EP3395358B1 (fr)	2012-09-26	2019-11-06	Indiana University Research and Technology Corporation	Dimères d'un analogue d'insuline
JP6538645B2 (ja)	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン‐インクレチン複合物
WO2014205617A1 (fr) *	2013-06-24	2014-12-31	Shandong University	Peptide marqué au lanthanide et utilisation de celui-ci
US20160271265A1 (en)	2013-10-02	2016-09-22	Novartis Ag	Insulin-like growth factor mimetics for use in therapy
UY35874A (es)	2013-12-12	2015-07-31	Novartis Ag	Un proceso para la preparación de una composición de proteínas pegiladas
CN108271356A (zh)	2014-09-24	2018-07-10	印第安纳大学研究及科技有限公司	肠降血糖素-胰岛素缀合物
JP6701208B2 (ja)	2014-09-24	2020-05-27	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	脂質化アミド系インスリンプロドラッグ
CN109072242A (zh) *	2016-02-23	2018-12-21	科罗拉多州立大学董事会法人团体	用于治疗神经损伤的基于肽的方法
CN113329762A (zh) *	2018-12-19	2021-08-31	美国联合生物医学公司	用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
EP3911668A1 (fr)	2019-01-18	2021-11-24	The Regents of the University of Colorado, a body corporate	Peptides antimicrobiens alpha-hélicoïdaux amphipathiques pour le traitement d'infections par des agents pathogènes à gram-négatif

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ207842A (en)	1983-04-25	1988-02-12	Chiron Corp	Production of human insulin-like growth factor (igf) using cdna
IL71991A (en)	1983-06-06	1994-05-30	Genentech Inc	Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US6235488B1 (en)	1988-09-29	2001-05-22	Agilent Technologies, Inc.	Surface preparation for chemical-specific binding
DK0400472T3 (da)	1989-05-27	1996-05-13	Sumitomo Pharma	Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US6723699B1 (en) *	1989-06-05	2004-04-20	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) *	1989-06-05	1992-03-03	Cephalon, Inc.	Treating disorders by application of insulin-like growth factor
DE3924705A1 (de)	1989-07-26	1991-01-31	Boehringer Mannheim Gmbh	Heterobifunktionelle verbindungen
US5158875A (en) *	1989-08-25	1992-10-27	Amgen Inc.	Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) *	1990-02-03	1993-07-27	Max Planck Gesellschaft	Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5681814A (en)	1990-06-07	1997-10-28	Genentech, Inc.	Formulated IGF-I Composition
JP3051145B2 (ja)	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US5861373A (en)	1991-08-01	1999-01-19	Genentech, Inc	IGF-1 to improve the neural condition
EP0597033B1 (fr)	1991-08-01	1997-04-09	Genentech, Inc.	Igf-1 utilise pour ameliorer l'etat pathologique du systeme nerveux
EP0679095A1 (fr)	1992-11-25	1995-11-02	Amgen Boulder Inc.	Facteur de croissance insulinoide modifie
WO1995032003A1 (fr)	1994-05-24	1995-11-30	Amgen Boulder Inc.	Facteurs de croissance proches de l'insuline modifies
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5741776A (en) *	1995-05-22	1998-04-21	Genentech, Inc.	Method of administration of IGF-I
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP2001511162A (ja)	1997-02-06	2001-08-07	ノボノルディスクアクティーゼルスカブ	付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US20030204864A1 (en) *	2001-02-28	2003-10-30	Henry Daniell	Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US7067485B2 (en)	1997-11-07	2006-06-27	Chiron Corporation	IGF-I composition and its use
US6767892B1 (en)	1997-11-07	2004-07-27	Chrion Corporation	Compositions providing for increased IGF-I solubility
US6248546B1 (en)	1998-03-09	2001-06-19	Diagnostic Systems Laboratories, Inc.	Assay of IGFBP complex
WO1999055362A1 (fr)	1998-04-29	1999-11-04	Genentech, Inc.	Formulations de igf-i sechees par pulverisation
US6436897B2 (en)	1998-06-01	2002-08-20	Celtrix Pharmaceuticals, Inc.	Pharmaceutical formulations for IGF/IGFBP
EP0972838B1 (fr)	1998-07-15	2004-09-15	Roche Diagnostics GmbH	Système de sélection par complémentation d' une auxotrophie en absence d'antibiotique chez E. coli
JP2002535967A (ja)	1999-01-06	2002-10-29	ジェネンテック・インコーポレーテッド	インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU762351B2 (en)	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
AU763039B2 (en)	1999-04-08	2003-07-10	Genentech Inc.	Composition based on oppositely-charged polypeptides
US6596849B1 (en)	1999-05-28	2003-07-22	Academia Sinica	Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
ATE389416T1 (de) *	2000-05-16	2008-04-15	Genentech Inc	Behandlung von knorpelerkrankungen
CA2410974A1 (fr) *	2000-05-16	2002-11-15	Dnavec Research Inc.	Polypeptides de clivage de repetitions telomeriques
EP1286700A2 (fr)	2000-06-01	2003-03-05	Universite Catholique De Louvain	Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
US20040014652A1 (en)	2000-06-01	2004-01-22	Andre Trouet	Tumor activated prodrug compounds and methods of making and using the same
US20020082215A1 (en)	2000-10-13	2002-06-27	Chiron Corporation	Method for treating ischemic events affecting the central nervous system
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU2002259281A1 (en)	2001-05-21	2002-12-03	Nektar Therapeutics Al, Corporation	Antibodies specific for poly(ethylene glycol)
GEP20084487B (en) *	2002-12-26	2008-09-25	Mountain View Pharmaceuticals	Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
EP1674113A1 (fr) *	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Conjugués de l'IGF-1 et du poly(éthylène glycol)
JP4988599B2 (ja)	2005-01-07	2012-08-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
AU2007245164A1 (en) *	2006-03-28	2007-11-08	Biogen Idec Ma Inc.	Anti-IGF-IR antibodies and uses thereof
CL2007002502A1 (es)	2006-08-31	2008-05-30	Hoffmann La Roche	Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP5173018B2 (ja)	2008-04-03	2013-03-27	エフ．ホフマン−ラロシュアーゲー	神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用

2007
- 2007-08-28 CL CL200702502A patent/CL2007002502A1/es unknown
- 2007-08-29 BR BRPI0715943-9A patent/BRPI0715943A2/pt not_active IP Right Cessation
- 2007-08-29 ES ES07801961T patent/ES2397660T3/es active Active
- 2007-08-29 AU AU2007291502A patent/AU2007291502B2/en not_active Ceased
- 2007-08-29 JP JP2009525971A patent/JP5184532B2/ja not_active Expired - Fee Related
- 2007-08-29 TW TW096132101A patent/TW200819468A/zh unknown
- 2007-08-29 AR ARP070103823A patent/AR062575A1/es not_active Application Discontinuation
- 2007-08-29 US US11/846,857 patent/US7625996B2/en not_active Expired - Fee Related
- 2007-08-29 CA CA2662062A patent/CA2662062C/fr not_active Expired - Fee Related
- 2007-08-29 WO PCT/EP2007/007540 patent/WO2008025528A1/fr not_active Ceased
- 2007-08-29 PE PE2007001177A patent/PE20080912A1/es not_active Application Discontinuation
- 2007-08-29 CN CN2007800319871A patent/CN101511390B/zh not_active Expired - Fee Related
- 2007-08-29 KR KR1020097003975A patent/KR101106931B1/ko not_active Expired - Fee Related
- 2007-08-29 RU RU2009106118/10A patent/RU2009106118A/ru not_active Application Discontinuation
- 2007-08-29 EP EP07801961A patent/EP2059261B1/fr active Active
- 2007-08-29 MX MX2009002011A patent/MX2009002011A/es active IP Right Grant
2009
- 2009-01-26 IL IL196736A patent/IL196736A/en active IP Right Grant
- 2009-01-29 CR CR10591A patent/CR10591A/es not_active Application Discontinuation
- 2009-01-29 NO NO20090451A patent/NO20090451L/no not_active Application Discontinuation
- 2009-01-30 CO CO09008773A patent/CO6251278A2/es not_active Application Discontinuation
- 2009-02-25 MA MA31660A patent/MA30660B1/fr unknown
- 2009-10-09 US US12/576,266 patent/US20100035817A1/en not_active Abandoned
2010
- 2010-04-27 US US12/767,829 patent/US20100210547A1/en not_active Abandoned
2012
- 2012-08-21 US US13/590,549 patent/US8476232B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101511390A (zh)	2009-08-19
KR101106931B1 (ko)	2012-01-25
AU2007291502B2 (en)	2012-05-31
US20080119409A1 (en)	2008-05-22
IL196736A (en)	2013-10-31
MX2009002011A (es)	2009-03-05
US8476232B2 (en)	2013-07-02
US7625996B2 (en)	2009-12-01
CR10591A (es)	2009-04-03
PE20080912A1 (es)	2008-07-19
AR062575A1 (es)	2008-11-19
US20130065831A1 (en)	2013-03-14
WO2008025528A1 (fr)	2008-03-06
EP2059261A1 (fr)	2009-05-20
CO6251278A2 (es)	2011-02-21
CA2662062A1 (fr)	2008-03-06
IL196736A0 (en)	2009-11-18
CA2662062C (fr)	2015-06-23
TW200819468A (en)	2008-05-01
US20100035817A1 (en)	2010-02-11
BRPI0715943A2 (pt)	2013-07-30
US20100210547A1 (en)	2010-08-19
JP5184532B2 (ja)	2013-04-17
RU2009106118A (ru)	2010-10-10
KR20090046875A (ko)	2009-05-11
ES2397660T3 (es)	2013-03-08
CN101511390B (zh)	2013-04-24
EP2059261B1 (fr)	2012-10-24
JP2010501192A (ja)	2010-01-21
AU2007291502A1 (en)	2008-03-06
MA30660B1 (fr)	2009-08-03
CL2007002502A1 (es)	2008-05-30

Legal Events

Date	Code	Title	Description
2012-03-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20090451L (no)	2009-02-26	Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol)
WO2008025527A8 (fr)	2009-07-02	Procédé de production du facteur de croissance 1 analogue à l'insuline
US11142550B2 (en)	2021-10-12	Split inteins with exceptional splicing activity
ES2633894T3 (es)	2017-09-25	Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
AU2002257243A1 (en)	2002-11-18	Rapidly cleavable sumo fusion protein expression system for difficult to express proteins
Malik	2016	Protein fusion tags for efficient expression and purification of recombinant proteins in the periplasmic space of E. coli
Yang et al.	2012	Expression and purification of the antimicrobial peptide cecropin AD by fusion with cationic elastin-like polypeptides
DK1874932T3 (da)	2013-02-04	Produktion af rekombinante proteiner ved autoproteolytisk spaltning af et fusionsprotein
RU2017123283A (ru)	2019-01-09	Партнеры по слиянию для получения пептидов
ATE421977T1 (de)	2009-02-15	Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
Liew et al.	2005	Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites
WO2007095320A4 (fr)	2014-12-24	Antigènes du papillomavirus humain, compositions de vaccin et méthodes
US20160168226A1 (en)	2016-06-16	Process for production of insulin and insulin analogues
WO2007125371A3 (fr)	2008-03-13	Procédé de production d'oligopeptides
Wang et al.	2016	A novel strategy for the preparation of codon-optimized truncated Ulp1 and its simplified application to cleavage the SUMO fusion protein
KR20140004219A (ko)	2014-01-10	대장균에서 이형 단백질 생산을 위한 새로운 발현 및 분비 벡터 시스템
US20160122793A1 (en)	2016-05-05	Fusion Protease
DK1905839T3 (da)	2011-04-18	Fremgangsmåde til fermentativ fremstilling af proteiner
CN106366201A (zh)	2017-02-01	融合蛋白damp4‑igf‑1的基因序列、载体、重组菌株、重组蛋白及其制备方法
GB201102700D0 (en)	2011-03-30	Protein secretion
JP2015502167A5 (fr)	2016-02-12
WO2016161983A1 (fr)	2016-10-13	Protéine porteuse hybride et application associée dans la promotion de protéine cible dans l'expression de polypeptide
CN104263747B (zh)	2017-03-15	一种长效蛋白质药物表达复性修饰的双标签载体及方法
JP2026507112A (ja)	2026-02-27	ペプチドの産生及び精製のための方法及び組成物
WO2014097323A1 (fr)	2014-06-26	Nouvelles étiquettes de fusion et système de vecteur d'expression pour l'expression de la parathormone humaine (rhpth)